KALA BIO (KALA) Expected to Announce Quarterly Earnings on Thursday

by · The Cerbat Gem

KALA BIO (NASDAQ:KALA – Get Free Report) is expected to be releasing its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect KALA BIO to announce earnings of ($6.00) per share for the quarter. Parties may visit the the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Friday, August 14, 2026 at 12:30 PM ET.

KALA BIO (NASDAQ:KALA – Get Free Report) last issued its earnings results on Friday, May 15th. The company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($8.50) by $8.36.

KALA BIO Stock Performance

KALA stock opened at $0.74 on Wednesday. The stock’s 50 day simple moving average is $1.80 and its 200 day simple moving average is $9.74. KALA BIO has a fifty-two week low of $0.59 and a fifty-two week high of $1,030.00. The company has a market cap of $14.37 million, a P/E ratio of -0.01 and a beta of -2.26.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the stock. Geode Capital Management LLC boosted its position in shares of KALA BIO by 2.8% during the second quarter. Geode Capital Management LLC now owns 56,367 shares of the company’s stock valued at $268,000 after buying an additional 1,534 shares during the last quarter. XTX Topco Ltd bought a new position in KALA BIO during the 2nd quarter valued at $62,000. Virtu Financial LLC bought a new position in KALA BIO during the 4th quarter valued at $48,000. Jane Street Group LLC purchased a new position in KALA BIO during the 4th quarter worth $80,000. Finally, Woodline Partners LP purchased a new position in KALA BIO during the 1st quarter worth $1,483,000. Institutional investors own 24.61% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. Wall Street Zen downgraded KALA BIO from a “hold” rating to a “sell” rating in a report on Sunday, July 12th. Weiss Ratings reiterated a “sell (e+)” rating on shares of KALA BIO in a report on Wednesday, June 24th. One analyst has rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, KALA BIO has a consensus rating of “Hold” and an average target price of $1,158.33.

Read Our Latest Research Report on KALA BIO

About KALA BIO

(Get Free Report)

KALA Bio (NASDAQ: KALA) is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for ocular diseases. The company’s proprietary surface charge–based nanoparticle delivery platform is designed to enhance penetration and retention of therapeutic agents on the ocular surface. This technology is the basis for its lead product, Eysuvis (KPI-121 1.0%), an FDA-approved topical corticosteroid for short-term relief of ocular itching associated with allergic conjunctivitis.

Beyond its approved therapy, KALA Bio is advancing a pipeline of investigational drug candidates targeting inflammatory and degenerative eye conditions.

Featured Stories